• Cardiff Oncology disclosed positive Phase 2 results for onvansertib with standard chemotherapy in first-line RAS-mutated metastatic colorectal cancer.
• Data were presented at the 2026 ASCO Annual Meeting, showing improved tumor response and longer disease control versus standard-of-care alone.
• Safety profile remained consistent with standard treatment, with no new or additive toxicities reported.
• A registrational Phase 3 trial is planned, testing onvansertib with FOLFIRI/bevacizumab against FOLFIRI/bevacizumab in the same setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiff Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606020906PRIMZONEFULLFEED9730212) on June 02, 2026, and is solely responsible for the information contained therein.